Catalent (CTLT.US), a contract pharmaceutical manufacturer whose clients include giants like Moderna, Johnson & Johnson, and Novo Nordisk, has announced a delay in the publication of its highly anticipated Q1 report. The company also indicated that it expects to significantly reduce its forecasts for the remainder of the year. Investors reacted with panic, resulting in a significant decline in the company's stock price. Catalent attributed the delay and reduced forecasts to performance issues and higher costs at three of its facilities. These issues are expected to impact both company profits and prospects. The company has acknowledged previous forecast discrepancies and is currently working to address these issues.
-
Catalent is going to lower its annual revenue projections by over $400 million. The final report has been rescheduled for May 15th to allow for adjustments in the financial statements.Â
-
The company has signaled performance issues and warned that slower-than-expected growth in production capabilities will weigh on results.Â
-
Catalent has estimated a goodwill impairment of over $200 million primarily related to the acquisition of Bettera Wellness.
-
In February, Catalent had forecasted full-year net revenues between $4.63 billion and $4.88 billion, along with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) between $1.22 billion and $1.30 billion.
-
According to analysts, quality and transparency issues may harm the company's reputation and its relationships with current and future clients.
-
Catalent was the sole manufacturer of Novo Nordisk's weight-loss drug Wegovy. However, the Danish company has not been affected by this and has already revealed a second producer last month to meet the growing demand.
Recently, the company's debt has been increasing at a faster rate than the valuation of its assets, as of May 5th. The debt-to-equity ratio stands at approximately 0.93, indicating that the company's asset valuation is at a similar level to its overall level of debt. Source: SimplyWallStreet.
Kezdjen befektetni még ma, vagy próbålja ki ingyenes demónkat
ĂlĆ szĂĄmla regisztrĂĄciĂł DEMĂ SZĂMLA Mobil app letöltĂ©se Mobil app letöltĂ©se
After a massive downward gap, Catalent shares are retracing close to the low of the March 2020 sell-off. Source: xStation5.
Ezen tartalmat az XTB S.A. kĂ©szĂtette, amelynek szĂ©khelye VarsĂłban talĂĄlhatĂł a következĆ cĂmen, Prosta 67, 00-838 VarsĂł, LengyelorszĂĄg (KRS szĂĄm: 0000217580), Ă©s a lengyel pĂ©nzĂŒgyi hatĂłsĂĄg (KNF) felĂŒgyeli (sz. DDM-M-4021-57-1/2005). Ezen tartalom a 2014/65/EU irĂĄnyelvĂ©nek, ami az EurĂłpai Parlament Ă©s a TanĂĄcs 2014. mĂĄjus 15-i hatĂĄrozata a pĂ©nzĂŒgyi eszközök piacairĂłl , 24. cikkĂ©nek (3) bekezdĂ©se , valamint a 2002/92 / EK irĂĄnyelv Ă©s a 2011/61 / EU irĂĄnyelv (MiFID II) szerint marketingkommunikĂĄciĂłnak minĆsĂŒl, tovĂĄbbĂĄ nem minĆsĂŒl befektetĂ©si tanĂĄcsadĂĄsnak vagy befektetĂ©si kutatĂĄsnak. A marketingkommunikĂĄciĂł nem befektetĂ©si ajĂĄnlĂĄs vagy informĂĄciĂł, amely befektetĂ©si stratĂ©giĂĄt javasol a következĆ rendeleteknek megfelelĆen, Az EurĂłpai Parlament Ă©s a TanĂĄcs 596/2014 / EU rendelete (2014. ĂĄprilis 16.) a piaci visszaĂ©lĂ©sekrĆl (a piaci visszaĂ©lĂ©sekrĆl szĂłlĂł rendelet), valamint a 2003/6 / EK eurĂłpai parlamenti Ă©s tanĂĄcsi irĂĄnyelv Ă©s a 2003/124 / EK bizottsĂĄgi irĂĄnyelvek hatĂĄlyon kĂvĂŒl helyezĂ©sĂ©rĆl / EK, 2003/125 / EK Ă©s 2004/72 / EK, valamint az (EU) 2016/958 bizottsĂĄgi felhatalmazĂĄson alapulĂł rendelet (2016. mĂĄrcius 9.) az 596/2014 / EU eurĂłpai parlamenti Ă©s tanĂĄcsi rendeletnek a szabĂĄlyozĂĄsi technikai szabĂĄlyozĂĄs tekintetĂ©ben törtĂ©nĆ kiegĂ©szĂtĂ©sĂ©rĆl a befektetĂ©si ajĂĄnlĂĄsok vagy a befektetĂ©si stratĂ©giĂĄt javaslĂł vagy javaslĂł egyĂ©b informĂĄciĂłk objektĂv bemutatĂĄsĂĄra, valamint az egyes Ă©rdekek vagy összefĂ©rhetetlensĂ©g utĂĄni jelek nyilvĂĄnossĂĄgra hozatalĂĄnak technikai szabĂĄlyaira vonatkozĂł szabvĂĄnyok vagy egyĂ©b tanĂĄcsadĂĄs, ideĂ©rtve a befektetĂ©si tanĂĄcsadĂĄst is, az A pĂ©nzĂŒgyi eszközök kereskedelmĂ©rĆl szĂłlĂł, 2005. jĂșlius 29-i törvĂ©ny (azaz a 2019. Ă©vi Lap, mĂłdosĂtott 875 tĂ©tel). Ezen marketingkommunikĂĄciĂł a legnagyobb gondossĂĄggal, tĂĄrgyilagossĂĄggal kĂ©szĂŒlt, bemutatja azokat a tĂ©nyeket, amelyek a szerzĆ szĂĄmĂĄra a kĂ©szĂtĂ©s idĆpontjĂĄban ismertek voltak , valamint mindenfĂ©le Ă©rtĂ©kelĂ©si elemtĆl mentes. A marketingkommunikĂĄciĂł az ĂgyfĂ©l igĂ©nyeinek, az egyĂ©ni pĂ©nzĂŒgyi helyzetĂ©nek figyelembevĂ©tele nĂ©lkĂŒl kĂ©szĂŒl, Ă©s semmilyen mĂłdon nem terjeszt elĆ befektetĂ©si stratĂ©giĂĄt. A marketingkommunikĂĄciĂł nem minĆsĂŒl semmilyen pĂ©nzĂŒgyi eszköz eladĂĄsi, felajĂĄnlĂĄsi, feliratkozĂĄsi, vĂĄsĂĄrlĂĄsi felhĂvĂĄsĂĄnak, hirdetĂ©sĂ©nek vagy promĂłciĂłjĂĄnak. Az XTB S.A. nem vĂĄllal felelĆssĂ©get az ĂgyfĂ©l ezen marketingkommunikĂĄciĂłban foglalt informĂĄciĂłk alapjĂĄn tett cselekedeteiĂ©rt vagy mulasztĂĄsaiĂ©rt, kĂŒlönösen a pĂ©nzĂŒgyi eszközök megszerzĂ©sĂ©Ă©rt vagy elidegenĂtĂ©sĂ©Ă©rt. Abban az esetben, ha a marketingkommunikĂĄciĂł bĂĄrmilyen informĂĄciĂłt tartalmaz az abban megjelölt pĂ©nzĂŒgyi eszközökkel kapcsolatos eredmĂ©nyekrĆl, azok nem jelentenek garanciĂĄt vagy elĆrejelzĂ©st a jövĆbeli eredmĂ©nyekkel kapcsolatban.
